New model offers a unique method to study Parkinson’s disease
Mice with rod-specific VPS35 deletion demonstrate a pathology more similar to human Parkinson’s disease, compared to other mouse models.
List view / Grid view
Mice with rod-specific VPS35 deletion demonstrate a pathology more similar to human Parkinson’s disease, compared to other mouse models.
Human brain organoids are complex in vitro tools derived from stem cells, designed to model the molecular basis of neurodevelopment and the pathogenesis of neurological disorders. By mimicking the function of the human brain, in both health and disease, their application in drug discovery holds significant potential for identifying new…
Researchers found that relaxing glial spacing by targeting Plexin-B1 has great therapeutic potential for Alzheimer’s disease.
The world’s first generation of human BBB organoids from hPSCs accurately replicated features of cerebral cavernous malformation.
Researchers identified miR-519a-3p as a biomarker that could enable early diagnosis and treatment of neurodegenerative diseases.
The discovery that CNTN4 and APP have a co-dependent relationship has wider implications for neurodevelopmental disorder understanding.
In this Q&A, we speak to Dr Emma Murphy, Head of Biology at the Alzheimer’s Research UK Oxford Drug Discovery Institute. Among her many insights, she discusses how the challenges in developing reproducible assays can be addressed, as well as strategies used to translate promising findings into clinically relevant tools…
Researchers find the mechanism which may underly the onset and progression of age-related neurodegenerative diseases.
The new study found T3s treatment exhibited neuroprotective effects in HFSD-fed mice by mitigating oxidative stress.
Researchers have presented new findings that offer potential pathways to arrest critical steps toward the accumulation of mutant tau.
Transplant recipients of hematopoietic stem cells with a hereditary version of AD developed the disease at an accelerated rate.
New findings about how long genes become less active with age could impact treatments for neurodegeneration, among other conditions.
Whole genome sequencing identified 17 significant variants associated with AD risk in five genomic regions.
Researchers have found that using protein-like polymers to inhibit the Keap1/Nrf2 PPI is a powerful therapeutic strategy.
A new learning-based framework enables patients and caregivers to predict the timing of any of the five clinical groups of AD development.